-transparent.png){kind=logo}
Cell factors of nonspecific immunity were estimated in 99 patients with different stages of melanoblastoma by delayed hypersensitivity skin test to tuberculin and DNCB (2,4-dinitrochlorobenzene). The skin test to DNCB is found to correlate with the clinical manifestations of the disease, while the skin test to tuberculin is not related with the degree of tumor spread. It is considered not rational to use the test concerned to define one of the immune cell factors in patients with melanoblastoma during the tumor progression.
Related Publications
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
July 1982,
Journal of the American Geriatrics Society,
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
March 1970,
Journal of immunology (Baltimore, Md. : 1950),
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
January 1971,
Revue francaise d'allergologie,
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
September 2022,
Pharmaceuticals (Basel, Switzerland),
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
July 1967,
Science (New York, N.Y.),
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
May 2022,
Immunology and allergy clinics of North America,
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
October 1974,
Cancer,
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
October 1969,
British journal of pharmacology,
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
April 1982,
The British journal of surgery,
V I Ryzhkov, and
L S Potapenkova, and
T A Korosteleva, and
L M Khachaturian
July 1977,
Immunology,
